Abstract
Treatment of Chronic Prostatitis with Phosphodiesterase Type 5 Inhibitors
Department of Urology, College of Medicine, Majmaah University, Al-Majmaah 15341, 1Department of Surgery, Division of Urology, College of Medicine, King Saud University, Riyadh 11362, 2Department of Urology, Armed Forces Hospital Southern Region, Khamis Mushayt, Tamniah 62413, 3Department of Urology, King Khaled University Medical City, Abha 62523, 4Department of Urology, National Guard Health Affairs, Jeddah, 5Department of Urology, King Faisal Medical City for Southern Region (KFMC), Abha 62527, 6Department of Urology, Aseer Central Hospital, Abha 21411, 7Department of Urology, King Fahad Medical City, Riyadh 12231, Saudi Arabia
Correspondence Address:
M. A. Alzahrani, Department of Urology, College of Medicine, Majmaah University, Al-Majmaah 15341, Saudi Arabia, E-mail: ma.alzahrani@mu.edu.sa
Our major aim was to systematically study the effectiveness of phosphodiesterase type 5 inhibitors in treating chronic prostatitis stage III and performed meta-analysis to evaluate the changes occurred in posttreatment scores of National Institutes of Health chronic prostatitis symptom index, international index of erectile function and international prostate symptom score. This meta-analysis was conducted according to the preferred reporting items for systematic reviews and meta-analyses guidelines. Comprehensive research was performed by using online resources like PubMed and the Wiley online library database to gather the relevant literature produced from the y 2010 to 2022. Two authors were assigned to independently collect the relevant information including author name, region of study, study design, treatment, publication year, sample size, voiding parameters, study inclusion and exclusion criteria, urological conditions, drug type, international prostate symptom score, international index of erectile function score, etc. In final screening 17 relevant studies were found. Out of these 17, 5 contained surgical procedure while 4 were narrative analysis. One study was incomplete regarding information. Finally, 7 studies were included for analysis. Total of 584 patients were involved in the selected studies. Three out of seven are from Italy region while two are from Japan and one was from Korea and Egypt respectively. Most of these studies used tadalafil monotherapy while one placebo-controlled trial. A significant difference in pain score, international prostate symptom score domain and National Institutes of Health chronic prostatitis symptom index were observed after consuming 5 mg tadalafil monotherapy. Everyday consumption of oral phosphodiesterase type 5 gave positive outcomes in terms of voiding. A significant difference was observed after using tadalafil monotherapy in the majority of the studies. Hence, tadalafil alone can be used to treat the type III chronic prostatitis.
Full-Text | PDF
